Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Catheter Precision ( (VTAK) ) just unveiled an announcement.
On August 18, 2025, Catheter Precision announced the approval of its suture retention device, LockeT, for commercialization in the United Kingdom. This approval marks a significant milestone for the company, enhancing its market presence in Europe following the CE Mark approval in May 2025. LockeT is designed to improve patient comfort and recovery, enabling earlier discharge after cardiac procedures, which aligns with the NHS’s efforts to reduce waiting lists. The partnership with distributor HC21 is expected to facilitate LockeT’s market entry and support healthcare systems in the UK.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
VTAK faces significant financial and operational challenges with ongoing losses and negative cash flow. Technical analysis indicates bearish momentum, and valuation is weak with a negative P/E. Corporate events offer both opportunities with product sales growth and risks from leadership changes and dilution concerns.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the cardiac electrophysiology market. The company collaborates with physicians to advance technology for electrophysiology procedures, aiming to improve the treatment of cardiac arrhythmias.
Average Trading Volume: 778,444
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.2M
For an in-depth examination of VTAK stock, go to TipRanks’ Overview page.